Guo Jiuqi, Guo Xiaofan, Sun Yingxian, Li Zhao, Jia Pengyu
Department of Cardiology, The First Hospital of China Medical University, Shenyang, 110001, China.
Hypertens Res. 2022 May;45(5):775-788. doi: 10.1038/s41440-022-00885-5. Epub 2022 Mar 9.
Hypertension is a major modifiable risk factor that affects the global health burden. Despite the availability of multiple antihypertensive drugs, blood pressure is often not optimally controlled. The prevalence of true resistant hypertension in treated hypertensive patients is ~2-20%, and these patients are at higher risk for adverse events and poor clinical outcomes. Therefore, an in-depth dissection of the pathophysiological mechanisms of hypertension and resistant hypertension is needed to identify more effective targets for regulating blood pressure. Omics technologies, such as genomics, transcriptomics, proteomics, metabolomics, and microbiomics, can accurately present the characteristics of organisms at varying molecular levels. Integrative omics can further reveal the network of interactions between molecular levels and provide a complete dynamic view of the organism. In this review, we describe the applications, progress, and challenges of omics technologies in hypertension. Specifically, we discuss the application of omics in resistant hypertension. We believe that omics approaches will produce a better understanding of the pathogenesis of hypertension and resistant hypertension and improve diagnostic and therapeutic strategies, thus increasing rates of blood pressure control and reducing the public health burden of hypertension.
高血压是一个主要的可改变风险因素，影响着全球健康负担。尽管有多种抗高血压药物，但血压往往得不到最佳控制。在接受治疗的高血压患者中，真正难治性高血压的患病率约为2%-20%，这些患者发生不良事件和临床结局不佳的风险更高。因此，需要深入剖析高血压和难治性高血压的病理生理机制，以确定更有效的血压调节靶点。组学技术，如基因组学、转录组学、蛋白质组学、代谢组学和微生物组学，能够在不同分子水平上准确呈现生物体的特征。整合组学可以进一步揭示分子水平之间的相互作用网络，并提供生物体的完整动态视图。在本综述中，我们描述了组学技术在高血压中的应用、进展和挑战。具体而言，我们讨论了组学在难治性高血压中的应用。我们相信，组学方法将更好地理解高血压和难治性高血压的发病机制，并改善诊断和治疗策略，从而提高血压控制率，减轻高血压的公共卫生负担。
